Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Immunovant's enterprise value was $6.84B on Nov 11, 2026, against $3.69B a year earlier. Over the last 5 years it ranged from -$39.53M to $7.62B, with a median of $3.06B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $6.84B | +74.8% |
| 2025 | Dec 31, 2025 | $3.91B | +24.0% |
| 2024 | Dec 31, 2024 | $3.16B | -40.1% |
| 2023 | Dec 29, 2023 | $5.27B | +216.5% |
| 2022 | Dec 30, 2022 | $1.66B | +295.4% |
| 2021 | Dec 31, 2021 | $420.84M | -89.7% |
| 2020 | Dec 31, 2020 | $4.08B | +2328.6% |
| 2019 | Dec 31, 2019 | $167.88M | – |
See a number that looks wrong?